| Alluzience, 200 Speywood units/mL, solution for injection PA1613/004/001 |
Botulinum Toxin A - Haemagglutinin Complex |
Ipsen Pharma |
Marketed |
| Azzalure, 125 Speywood units, powder for solution for injection PA1613/001/001 |
Clostridium botulinum toxin type a haemagglutinin complex |
Ipsen Pharma |
Marketed |
| Bylvay 1 200 micrograms hard capsules EU/1/21/1566/004 |
Odevixibat sesquihydrate |
Ipsen Pharma |
— |
| Bylvay 200 micrograms hard capsules EU/1/21/1566/001 |
Odevixibat sesquihydrate |
Ipsen Pharma |
— |
| Bylvay 400 micrograms hard capsules EU/1/21/1566/002 |
Odevixibat sesquihydrate |
Ipsen Pharma |
— |
| Bylvay 600 micrograms hard capsules EU/1/21/1566/003 |
Odevixibat sesquihydrate |
Ipsen Pharma |
— |
| CABOMETYX 20 mg film-coated tablets EU/1/16/1136/001-002 |
Cabozantinib |
Ipsen Pharma |
— |
| CABOMETYX 40 mg film-coated tablets EU/1/16/1136/003-004 |
Cabozantinib |
Ipsen Pharma |
— |
| CABOMETYX 60 mg film-coated tablets EU/1/16/1136/005-006 |
Cabozantinib |
Ipsen Pharma |
— |
| COMETRIQ 20 mg hard capsules EU/1/13/890/001 |
Cabozantinib (s)-malate |
Ipsen Pharma |
— |
| COMETRIQ 80 mg hard capsules EU/1/13/890/002-003 |
Cabozantinib (s)-malate |
Ipsen Pharma |
— |
| Decapeptyl 3-month, 11.25 mgPowder and solvent for suspension for injection PA0869/003/002 |
Triptorelin |
Ipsen Pharmaceuticals Limited |
Marketed |
| Decapeptyl 6-month 22.5 mg Powder and solvent for prolonged-release suspension for injection PA0869/003/003 |
Triptorelin pamoate |
Ipsen Pharmaceuticals Limited |
Marketed |
| Decapeptyl SR, 3 mg powder and solvent for suspension for injection PA0869/003/001 |
Triptorelin |
Ipsen Pharmaceuticals Limited |
Marketed |
| Dysport 300 units Powder for solution for injection PA1613/002/002 |
Botulinum toxin type A - haemagglutinin complex |
Ipsen Pharma |
Marketed |
| Dysport 500 units Powder for solution for injection PA1613/002/001 |
Clostridium botulinum toxin type a haemagglutinin complex |
Ipsen Pharma |
Marketed |
| Iqirvo 80 mg film-coated tablets EU/1/24/1855/001 |
Elafibranor |
Ipsen Pharma |
— |
| KAYFANDA 1200 microgram hard capsules EU/1/24/1854/004 |
Odevixibat |
Ipsen Pharma |
— |
| KAYFANDA 200 microgram hard capsules EU/1/24/1854/001 |
Odevixibat |
Ipsen Pharma |
— |
| KAYFANDA 400 microgram hard capsules EU/1/24/1854/002 |
Odevixibat |
Ipsen Pharma |
— |
| KAYFANDA 600 microgram hard capsules EU/1/24/1854/003 |
Odevixibat |
Ipsen Pharma |
— |
| NutropinAq 10 mg/2 ml solution for injection EU/1/00/164/003-004 |
Somatropin |
Ipsen Pharma |
— |
| NutropinAq 10 mg/2 ml solution for injection EU/1/00/164/005 |
Somatropin |
Ipsen Pharma |
— |
| Relfydess, 100 units/mL, solution for injection PA1613/005/001 |
Botulinum Toxin Type A |
Ipsen Pharma |
Marketed |
| Salvacyl, 11.25 mg powder and solvent for prolonged-release suspension for injection PA0869/008/001 |
Triptorelin |
Ipsen Pharmaceuticals Limited |
Not marketed |
| Somatuline Autogel 120mg, solution for injection in a pre-filled syringe PA0869/004/004 |
Lanreotide acetate |
Ipsen Pharmaceuticals Limited |
Marketed |
| Somatuline Autogel 60 mg, solution for injection in a prefilled syringe PA0869/004/002 |
Lanreotide acetate |
Ipsen Pharmaceuticals Limited |
Marketed |
| Somatuline Autogel 90mg, solution for injection in a pre-filled syringe PA0869/004/003 |
Lanreotide acetate |
Ipsen Pharmaceuticals Limited |
Marketed |